Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch
Plans for launching a second Alzheimer's drug, lecanemab, will be scaled back compared to Aduhelm, the firm predicted, though partner Eisai has not finalized Biogen's commercial role yet.
You may also be interested in...
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.
In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.